A.MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer(s) responsible for batch release
Accord Healthcare Ltd. Sage House
319 Pinner road
North Harrow, Middlesex HA1 4HF United Kingdom
The printed package leaflet of the medicinal product must state the name and address of the Manufacturer responsible for the release of the concerned batch.
B.CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
- Bondronat - ibandronic acid
- Ibandronic acid sandoz - ibandronic acid
- Bondenza (ibandronic acid roche) - ibandronic acid
- Bonviva - ibandronic acid
- Iasibon - ibandronic acid
Prescription drugs listed. Substance: "Ibandronic acid"
Ibandronic acid Accord 2 mg and 6 mg concentrate for solution for infusion (for oncology indications):
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Ibandronic acid Accord 3 mg solutionfor injection (for osteoporosos indications): Medicinal product subject to medical prescription.
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
•Periodic Safety Update Reports
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
- Pioglitazone accord - Accord Healthcare Ltd
- Aripiprazole accord - Accord Healthcare Ltd
- Docetaxel accord - Accord Healthcare Ltd
- Capecitabine accord - Accord Healthcare Ltd
- Granpidam - Accord Healthcare Ltd
- Ivabradine accord - Accord Healthcare Ltd
Prescription drugs listed. Manufacturer: "Accord Healthcare Ltd"
•Risk Management Plan (RMP)
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:
•At the request of the European Medicines Agency;
•Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.
Additional risk minimisation measures
The MAH shall ensure that a patient reminder card regarding osteonecrosis of the jaw is implemented.